Intas Pharmaceuticals

Intas Pharmaceuticals is one of India's top ten pharmaceutical companies and the largest privately held firm in the sector, generating over $1 billion in annual revenue, with 60% derived from international markets. The company operates in 70 countries, with a significant portion of its export revenue coming from the United States, United Kingdom, and European Union. Intas has more than ten manufacturing facilities that comply with global regulatory standards, ensuring a strong reputation for quality. It produces a diverse range of dosage forms, including solid orals, injectables, and biosimilars. The company employs around 12,000 individuals worldwide, including over 800 scientists, and invests approximately 6% of its sales into research and development, holding 27 international patents. Intas specializes in oncology products for various cancers and critical disorders, focusing on value-added pharmaceuticals, including innovative drug delivery systems and active pharmaceutical ingredients. It has the largest commercialized portfolio of biosimilars in India and was the first Indian company to introduce a biosimilar in the European market. Intas is headquartered in Ahmedabad, India, and is supported by financial investors such as Temasek and ChrysCapital.